Post-menopausal hormone replacement therapy increases the risk of veno
us thrombo-embolism 2- to 4-fold. The risk is highest in the beginning
of the exposure to hormones and disappears rapidly alter interruption
of treatment. However, the increased risk remains low in absolute val
ue and has to be weighed against coronary artery disease and post-meno
pausal osteoporosis.